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Diabetes mellitus (DM) is a chronic degenerative disease that impairs normal insulin production 
and use. DM chronic auditory complications may include spiral ganglion atrophy, degeneration of 
the vestibulocochlear nerve myelin sheath, reduction of the number of spiral lamina nerve fibers, 
and thickening of the capillary walls of the stria vascularis and small arteries.
Objective: This paper aims to verify the hearing thresholds of individuals with type 1 DM.
Materials and Methods: Sixty patients were enrolled in this trial and divided into case and control 
groups featuring diabetic and non-diabetic subjects respectively. All individuals were interviewed 
and underwent physical examination, ENT examination, and audiometric tests.
Results: Statistically significant difference was observed in hearing thresholds of case group subjects 
at 250, 500, 10,000, 11,200, 12,500, 14,000 and 16,000 Hz for both ears and ear average. Case group 
subjects had higher likelihood of having hypacusis at any frequency regardless of ear than controls.
Conclusion: Statistically significant differences were seen in the audiological findings of case group 
subjects when compared to controls. Thorough audiological examination including high frequency 
audiometry is required for subjects with diabetes mellitus type 1.
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INTRODUCTION
Diabetes mellitus (DM) is a chronic disease 
derived from the inadequate production of insulin in 
the pancreas or from the ineffective use of available 
insulin. It is characterized by increased blood sugar 
levels1 and is a genetically inherited disease2.
DM is a relevant chronic degenerative disorder. 
Prevalence rates vary regionally. It has been estimated 
that by 2025 there will be an astounding 300 million 
diabetic individuals in the world, twice as many as 
in 20001. Some five million Brazilians have diabetes 
and almost half of them are unaware of their condi-
tion. Late diagnosis occurs frequently, mainly among 
children and teens2.
There are four main types of DM: type 1 - 
results from the autoimmune destruction of the 
pancreatic beta-cells; type 2: insulin metabolism or 
secretion disorder; secondary diabetes related to 
genetic predisposition, drug use, unknown cause; 
gestational diabetes1.
DM type 2 accounts for 80% to 90% of all cases 
and is closely linked to obesity. DM type 1 accounts 
for the remaining 10% to 20% and affects 8.4:100,000 
people in Brazil. Eye, kidney, cranial nerve, periphe-
ral nerve, ear, and vascular system disorders reside 
among the chronic complications of diabetes mellitus. 
In the auditory system, DM may lead to spiral gan-
glion atrophy, degeneration of the myelin sheath of 
the vestibulocochlear nerve, reduction on the number 
of nerve fibers in the spiral lamina, and thickening 
of the capillary walls of the stria vascularis and small 
arteries inside the ear canal1.
There is some disagreement in regards to the 
pathological changes DM introduces to the auditory 
system. Various types of auditory involvement have 
been reported in diabetic subjects. One of them is the 
gradual onset of bilateral sensorineural hearing loss, 
involving mainly higher frequencies in elderly pa-
tients. This is similar to presbycusis, but with greater 
losses than expected for the age range. Other authors 
have reported sudden onset early sensorineural he-
aring loss affecting low and mid-range frequencies2.
There is no consensus in the literature as to the 
incidence of hearing loss related to DM, as reports 
range from 0 to 93%2.
Current research indicates that DM may cause 
hearing loss, but a firm cause-effect correlation has 
not been described yet. It is known that a series of 
variables may favor the association of both condi-
tions, but more studies are required to establish the 
true role these factors play. As seen above, diabetes 
and hearing loss may be interdependent components, 
or even components of a genetic syndrome2.
DM may be incurable, but it is a manageable 
condition. Therapy aims to avoid the complications 
consequent to the chronic evolution of DM, such 
as vascular, neurological, and metabolic disorders2.
Metabolic disorders are a relevant diagnostic 
component in the inner ear involvement secondary 
to DM. More studies are required to assess the audi-
tory signs and symptoms present in individuals with 
insulin-dependent DM3.
Given this scenario, the purpose of this paper 
is to verify the hearing thresholds of individuals with 
DM type 1.
Literature review
A lot has been discussed on the association 
between diabetes and hearing loss since it was first 
considered in 1857 by Jordão, but a clear relationship 
between these factors is yet to be established. In 
general terms, the literature presents contradictory 
information. The Framingham trial pointed to an as-
sociation between glucose levels and hearing loss in 
women. In 1997, the central and peripheral auditory 
pathways of DM type 2 patients were analyzed, and 
it was found that the cochlear receptor is the main 
structure affected in diabetic patients and that central 
auditory pathways showed no involvement4.
Hearing loss and diabetes mellitus
Today the association between DM and hea-
ring loss is being given a lot of attention. Complaints 
related to the auditory and vestibular systems and 
metabolic disorders affecting glycides and lipids have 
been pointed out as the main etiologic factors related 
to hearing loss, tinnitus, and dizziness5. Therefore, 
the diabetic population must be considered at risk 
for auditory conditions3.
Higher mean hearing thresholds have been 
reported (more hearing loss) in diabetic patients 
with neuropathy when compared to diabetic patients 
without neuropathy in all frequencies from 250 Hz to 
8.000 Hz. DM-related hearing loss follows a similar 
pattern to that of presbycusis given the linear distri-
bution between frequencies6.
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Hearing loss characteristics and diabetes mellitus
It has been reported that in patients with “dia-
betes in situ” (when routine workup cannot diagnose 
diabetes) hearing loss is usually fluctuating, as cha-
racterized in hydrops secondary to altered sodium/
potassium gradients and reduced endocochlear po-
tentials. As the disease progresses, microangiopathy 
and diabetic neuropathy assist in the progression of 
dysacusis7.
Dysacusis manifests gradually and progressive-
ly. It is usually a bilateral sensorineural condition that 
involves mainly higher frequencies. Sudden unilateral 
hearing loss may also occur. Diabetic angiopathy 
and neuropathy, either combined or separately, have 
been singled out as the cause for vestibulocochlear 
disorders as they affect the vessels in the inner ear 
and stria vascularis2.
Causes of hearing loss and diabetes mellitus
It has been reported that insulin resistance 
and hyperinsulinemia increase the rate of triglyceri-
de production8. Various papers have described the 
association between lipid and glycide disorders in 
patients with vertigo, stressing their higher risk for 
atherosclerosis and acute myocardial infarction9-12. 
However, changes in insulin serum levels in the 
long run may cause the acceleration of atheroscle-
rotic injuries in diabetic patients. In 1972 a report 
was published telling of an 86-year-old lady with 
recurring vertigo episodes. In her autopsy it was 
found that she had partial degeneration in the upper 
division of the vestibular nerves along with severe 
coronary atherosclerosis13. Degeneration was inter-
preted as secondary to atherosclerotic vasculopathy 
of the anterior vestibular artery, confirming the idea 
that glucose and insulin metabolic disorders affect 
microcirculation.
It is known that in order for the inner ear to 
function properly there has to be a good balance 
between insulin and glucose levels. DM patients 
have glucose in their blood, but it cannot enter the 
cells of the inner ear because of the lack of insulin 
thus producing functional disorders5. This may be an 
important etiologic factor in labyrinthine disorders14.
The main proposed mechanisms are the inter-
ference on nutrient transportation through thickened 
capillary walls, flow reductions due to narrowed 
vessels, and secondary degeneration of the vestibu-
locochlear nerve causing neuropathy15-17.
Angiopathy occurs mainly in the stria vascularis 
and on the spiral ligament. Studies in diabetic rats su-
ggest that hearing impairment is caused primarily by 
the reduction on the number of spiral ganglion cells 
and secondarily by edema in the stria vascularis18.
Some authors, however, insist that hypacusis 
progression occurs due to central auditory pathway 
involvement and not because of cochlear angiopathy 
progression19.
Spiral ganglion neuron atrophy and demye-
lination of the vestibulocochlear nerve have been 
described in four diabetic patients. It was shown that 
demyelination is also the early injury to the periphe-
ral nerves of extremities on diabetes and that traces 
of myelin metabolic disorder may have a relevant 
role in the pathogenesis of diabetic neuropathy. The 
following were observed through an optical micros-
cope: auditory nerve demyelination by degeneration 
of the myelin sheath with minor axon alterations 
and perineurium fibrosis; severe atrophy in the spi-
ral ganglion with cell loss in the basal and middle 
turn of the cochlea, and reduction on the number 
of nerve fibers of the spiral lamina. Other findings 
included reduction on the number of ganglion cells 
in the ventral and dorsal cochlear nuclei, minor loss 
of ganglion cells in the superior olivary nucleus, 
inferior colliculus, and medial geniculate body. No 
changes directly connected to DM were observed in 
the temporal lobe auditory centers20.
Other authors claim that neuropathy is the 
primary injury in hearing loss and that PAS-positive 
material found on vessel walls is non-specific, as it is 
also found in other conditions. Twenty patients with 
peripheral diabetic neuropathy underwent audiome-
tric testing and had their test results to those of 32 
controls without DM. The thresholds of individuals 
with peripheral neuropathy were always worse than 
those of the controls in all frequencies. The thresholds 
of patients above the age of 60 were also worse in 
both groups. Typically, subjects were found to have 
progressive sensorineural hearing loss, and patients 
above 60 had more intense involvement21.
Genetic syndromes have also been considered 
by other authors, once more cases of hypacusis have 
been observed in diabetic individuals with diabetic 
mothers in an inheritance pattern connected to mi-
tochondrial DNA2.
This association was first alluded to in a case 
of DM concurrent with sensorineural hearing loss 
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with onset at 30 years of age in maternal relatives 
of a German family22. In 1992, a mitochondrial DNA 
mutation was found to be present in all subjects with 
diabetes and deafness of maternal origin in members 
of the same family. This mutation is a replacement 
of nucleotide adenine by guanine on locus 3243 of 
the tRNA leucine encoding gene (tRNAleu)23.
In a prospective trial, Newkirk et al.24 repor-
ted the prevalence of DM and deafness of maternal 
inheritance in a population of diabetic patients at 
Newcastle Hospital. The authors defined the asso-
ciation as a new subtype of diabetes resulting from 
the replacement of adenine for guanine in locus 3243 
of mitochondrial gene tRNALeu (uur). They further 
stated this syndrome was originally identified as 
the cause for the MELAS syndrome (mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like 
episodes) and that sensorineural hearing loss appears 
as an additional symptom in about 70% of the cases.
The possible association with DNA mutations 
was first considered by Luft et al.25. The authors des-
cribed the case of a patient with non-thyroid hyper-
metabolism whose muscle biopsy revealed cells with 
paracrystalline mitochondrial inclusions.
This association was confirmed in 1986, when 
Petty et al.26 described the case of a patient with mito-
chondrial myopathy and hearing loss. Incidence rates 
of mitochondrial hearing loss seems to range from 0.5% 
to 1.0% in all causes related to genetic inheritance. In 
these cases the condition may categorized as follows: 
syndromic (when hearing loss is associated with other 
systemic manifestations) or non-syndromic (hearing 
loss alone).
Statistics reveal that the association between 
diabetes and hearing loss of maternal inheritance 
accounts for 1.5% of all cases of diabetes in the Ne-
therlands and Japan27.
The clinical characteristics of DM related to 
deafness of maternal inheritance are well established:
•	Insulin-dependent diabetes: at onset diabetes 
may not be of the insulin-dependent type, 
but it usually progresses to become insulin-
-dependent as mitochondrial disorders alter 
insulin secretion by the pancreas.
•	Inheritance is maternal only.
•	Patients are thin.
•	Onset occurs before 40 years of age.
•	Patients have sensorineural hearing loss, ini-
tially at higher frequencies; the condition is 
progressive and recruiting, suggestive of strictly 
cochlear involvement27.
Diabetic angiopathy has been characterized 
by endothelial proliferation, intimal accumulation of 
glycoproteins, and thickening of the capillary and 
small vessel basement membranes. Internal auditory 
artery wall fibrotic thickening and lumen stenosis 
were also observed. Accumulation of PAS-positive 
substance in the internal auditory artery walls, mo-
diolus vessels, and stria vascularis capillaries was 
also seen20.
Fukushima et al.28 looked into the effects of 
DM in the cochlear elements of human beings and 
concluded that DM type 1 patients may have cochlear 
microangiopathy and subsequent degeneration of the 
cochlear lateral walls and hair cells.
Glucose metabolism significantly affects the 
inner ear. Both low and high sugar levels may alter 
inner ear function. Patients with glucose metabolism 
disorders may have auditory, vestibular, or mixed 
symptoms as seen in diabetes7.
The inner ear presents intense metabolic acti-
vity, but has no energy storage capability. Therefore, 
minor sugar level changes affect inner ear func-
tion5,7,29. Whether it is the release of insulin by the 
pancreas or the changes in cell membrane receptors, 
inner ear metabolic disorders tend to present shifts 
in potassium from endolymph to perilymph and in 
sodium the opposite way, in a mechanism that trig-
gers vertigo, tinnitus, hypacusis, and aural fullness5.
The presence of severe peripheral neuropathy 
or retinopathy seems to increase the risk of hearing 
loss. However, there is no association between the 
duration and severity of diabetes and hearing loss30.
Groups with diabetes mellitus and greater chance 
of hearing loss
Some groups are at a greater risk of having 
hearing loss for various reasons and predisposing 
factors. Among such groups are the individuals ex-
posed to noise, patients taking ototoxic drugs, and 
subjects with metabolic disorders7,31.
Auditory complaints vary significantly, and may 
range from fluctuating hypacusis to sensorineural 
hearing loss. Tinnitus and aural fullness may also 
occur7,31.
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It has been found that high frequency hearing 
loss (similar to presbycusis) may be present in diabe-
tic patients before they reach the age of 60. After this 
age, the incidence of hearing loss is not significantly 
different for diabetic and non-diabetic subjects32.
Inner ear metabolism
The relevance of aerobic glucose metabolism 
in maintaining endolymphatic potential has been 
documented33. Although hair cells may use other 
substrates such as glutamate, pyruvate, or fumarate 
to maintain endolymphatic potential, none of them 
is as effective as glucose34,35. Glycogen may also be 
detected in the stria vascularis, but this alternative 
source of energy cannot handle potential maintenan-
ce in the absence of glucose36.
Hypoglycemia affects the active transportation 
of sodium and potassium and thus produces hydro 
electrolytic imbalances in the endolymph. Endolymph 
is similar to the intracellular medium in its make-up, 
as it is rich in potassium and poor in sodium. Perilym-
ph, on the other hand, is rich in sodium and poor in 
potassium, and is similar to the extracellular medium. 
As fluid are separated by a permeable membrane, 
potassium tends to shift from the endolymph to the 
perilymph, while sodium tends to go the opposite 
way. This passive spontaneous mechanism would 
lead to high sodium levels in the endolymph and to 
more water shifting into this compartment, causing 
the onset of endolymphatic hydrops and the ensuing 
clinical repercussions: vertigo, tinnitus, hypacusis, 
and aural fullness5.
The diagnosis of metabolic disorder is very 
relevant for ENTs and their patients, once inner ear 
involvement may be exacerbated of popular drugs 
for labyrinthine conditions such as cinnarizine and 
flunarizine are used, as they are vasoactive drugs that 
increase the consumption of glucose by nerve cells 
and thus strengthen metabolic disorders37.
Histology changes
In DM patients the histological alterations ob-
served are microangiopathy and peripheral neuro-
pathy. They impair terminal blood flow and glucose 
supply38. Some authors have also reported minimal 
cell disorder and functional involvement of the cen-
tral labyrinthine pathways as early DM complications 
unrelated to neuropathy or microangiopathy39-41.
A literature review mentioned that the capillary 
basement membrane is made up of collagen proteins 
commonly found in connective and scar tissues. The 
synthesis of these proteins is up-regulated in response 
to a variety of stimuli and injuries. The authors stated 
that capillary basement membrane thickening associa-
ted with diabetes is considered to be a proliferative 
response of capillary cells to injury. Others reported 
that thickening can be assigned to repeated episodes 
of endothelial cell death and regeneration (necrotic 
endothelial cells are trapped in the basement mem-
brane as new layers of tissue are formed by regene-
ration). They concluded that a wide range of in vivo 
and in vitro studies present data consistent with this 
assumption, and further suggest that the synthesis 
of the basement membrane and tissue regeneration 
are increased in diabetes while basement membrane 
degradation is reduced or impaired42.
The authors of a study done on the temporal 
bones of 32 individuals of various ages43 found that 
PAS-stained blood vessels of the stria vascularis 
revealed interesting findings. They found massive 
lamellar deposits of PAS on the capillary walls of the 
stria vascularis ten to twenty times thicker than usual. 
The alterations were similar to findings consistent 
with atherosclerosis, however in a less-pronounced 
manifestation in the stria vascularis. The authors ob-
served degeneration in other parts of the labyrinth, 
but they were consistent with temporal bone findings 
of non-diabetic subjects of the same age.
The study confirmed non-generalized angio-
pathy, as certain capillary systems of the inner are 
preferentially involved, as is the case of the stria 
vascularis. Nonetheless, the authors were unable 
to clearly establish the chemical nature of the pre-
cipitate, as numerous substances are dyed by this 
method. They reported that the findings are typical 
of diabetes, but not specific to the disease, observing 
that atherosclerosis is reduced peripherally, while 
diabetic angiopathy is intensified in the vicinity of 
small vessels43.
METHODS
Materials
Sixty individuals of both genders were enrolled 
in this study and divided into two groups.
Group 1: the case group was made up of thirty 
individuals with DM type 1, 17 (57%) males and 13 
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(43%) females with ages ranging from 18 to 55 years 
(mean age of 25.9 years; standard deviation of 10.4).
Group 2: the control group included 30 non-
-diabetic subjects. Clinical examination and workup 
(fasting glucose, cutoff point glucose levels below 
101) were done for all individuals. None of them had 
a family history of DM. Seventeen (57%) were males 
and 13 (43%) were females with ages ranging from 
18 to 55 years (mean age of 26.56 years; standard 
deviation of 9.6).
Audiological tests were done to rule out indivi-
duals from either of the groups with malformations, 
chronic otitis media, ear wax plug, or blood in their 
ears.
This study was approved by the Research Ethics 
Committee and given permit number 009/2005. Enrol-
led individuals signed an informed consent form, as 
per the guidelines and standards in effect for research 
using human beings.
Method
Members from both groups were first inter-
viewed to gather relevant data on indicators over ear 
symptoms. Controls were also interviewed to find 
our whether they had cases of DM in their families.
The following procedures were then carried 
out:
a) ENT assessment – otoscopic examination 
with device Welch Allyn model 20200 USA® to rule 
out disorders that could affect the study results.
b) Conventional audiological assessment – pu-
re-tone air conduction audiometry from 250 to 8000 
Hz, and bone conduction audiometry from 500 Hz to 
4000 Hz, followed by speech recognition threshold 
(SRT) and speech detection threshold (SDT) tests 
were carried out in a soundproof booth.
An AC40® Interacoustics audiometer and TDH-
39® earphones with thresholds in dBNA were used 
in the tests.
c) High-frequency audiological assessment - 
the audiometer mentioned above was used to test 
auditory thresholds for frequencies ranging from 9000 
Hz to 16000 Hz; KOOS HV/PRO® digital earphones 
with thresholds in dBNA were used in the tests.
High-frequency audiometry looks into fre-
quencies ranging from 9000 to 18000 Hz and is an 
important test in the early detection of hearing loss at 
the base of the cochlear duct. Auditory involvement 
can be detected before the conventional frequency 
range is compromised, and patients taking ototoxic 
drugs can be monitored to prevent spiral organ de-
terioration44.
The equipment was calibrated based on stan-
dard ISO 8253. The criteria developed by Davis and 
Silverman45,46 were used to assess adult patients. 
Individuals over 50 were analyzed based on the 
criteria proposed by International Organization for 
Standardization in Geneva (2000).
Statistical analysis
The results in this study are presented as mean, 
median, minimum, maximum values, and standard 
deviations (quantitative variables) or frequencies and 
percentages (qualitative variables).
The quantitative variables used to compare 
the case and control groups were treated using 
Student’s t-test for independent variables and the 
Mann-Whitney U test.
The qualitative dichotomic variables of 
both groups were compared using Fisher’s exact 
test. Statistical significance was attributed when p 
< 0.05. The data sets were treated with software 
Statistica v.8.0.
All tests had 0.05 or 5% as the threshold to test 
the null hypothesis. Significant values were marked 
with an asterisk.
RESULTS
Auditory thresholds (dBNA) for case and control 
groups for right and left ears and both genders
Table 1 presents the statistics on auditory 
thresholds based on the frequencies, groups, and 
ears studied. The p-values are also presented.
Following are the frequencies in which statisti-
cally significant difference was found with increased 
audiometric thresholds in case group subjects when 
compared to controls: 250, 500, 10000, 11200, 12500, 
14000 and 16000 Hz for both ears and mean values 
for both ears; and only right ears and mean values 
for both ears at 9.000 Hz.
Hypacusis probabilities for case and control groups
The analysis described below considered 
hearing loss occurred when subjects had auditory 
involvement at any frequency or ear.
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Table 1. Control and case group hearing thresholds for right (RE) and left ears (LE) from 250 Hz to 16000 Hz.
Frequency Side Group n
Hearing Threshold
p value
Mean Median Min. Max. Sd. Deviation
250Hz
RE
Control 30 9.0 10.0 0.0 15.0 3.8
2
Case 30 15.8 17.5 -10.0 60.0 12.6
LE
Control 30 7.3 7.5 0.0 15.0 4.3
< 0.001
Case 30 17.8 17.5 -10.0 60.0 14.5
Mean Control 30 8.2 10.0 0.0 12.5 3.5
< 0.001
RE/LE Case 30 16.8 15.0 -10.0 57.5 12.7
500Hz
RE
Control 30 7.5 10.0 0.0 15.0 4.7
5
Case 30 13.3 15.0 -10.0 55.0 11.1
LE
Control 30 7.8 7.5 0.0 20.0 5.7
22
Case 30 14.3 12.5 -10.0 60.0 13.6
Mean Control 30 7.7 7.5 0.0 17.5 4.8
0.008
RE/LE Case 30 13.8 12.5 -10.0 52.5 11.7
1KHz
RE
Control 30 6.5 5.0 0.0 20.0 5.4
0.103
Case 30 9.7 10.0 -10.0 50.0 10.2
LE
Control 30 7.3 5.0 0.0 20.0 6.4
0.155
Case 30 11.7 10.0 -5.0 55.0 13.1
Mean Control 30 6.9 5.0 0.0 20.0 5.8
0.106
RE/LE Case 30 10.7 7.5 -7.5 52.5 11.1
2KHz
RE
Control 30 7.0 7.5 0.0 20.0 5.8
0.741
Case 30 8.5 5.0 -10.0 55.0 13.8
LE
Control 30 8.5 10.0 0.0 20.0 5.1
0.467
Case 30 10.8 5.0 -5.0 60.0 16.0
Mean Control 30 7.8 7.5 0.0 17.5 4.9
0.542
RE/LE Case 30 9.7 5.0 -7.5 55.0 14.4
3KHz
RE
Control 30 6.3 5.0 0.0 25.0 6.0
0.644
Case 30 7.7 5.0 -10.0 60.0 13.9
LE
Control 30 6.5 5.0 0.0 20.0 6.3
0.406
Case 30 11.7 5.0 -10.0 65.0 17.7
Mean Control 30 6.4 5.0 0.0 20.0 5.8
0.971
RE/LE Case 30 9.7 5.0 -7.5 57.5 15.2
4KHz
RE
Control 30 10.2 5.0 0.0 30.0 8.6
0.832
Case 30 12.2 10.0 -10.0 70.0 16.7
LE
Control 30 8.8 5.0 0.0 20.0 7.4
0.458
Case 30 14.5 10.0 -5.0 65.0 17.5
Mean Control 30 9.5 7.5 0.0 22.5 7.2
0.912
RE/LE Case 30 13.3 10.0 -5.0 67.5 16.5
6KHz
RE
Control 30 11.2 10.0 0.0 35.0 8.6
0.936
Case 30 13.7 10.0 -10.0 70.0 17.5
LE
Control 30 9.3 10.0 0.0 35.0 8.4
0.697
Case 30 13.5 10.0 -5.0 60.0 16.1
Mean Control 30 10.3 10.0 0.0 35.0 7.9
0.971
RE/LE Case 30 13.6 10.0 -5.0 65.0 16.1
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8KHz
RE
Control 30 9.0 5.0 0.0 25.0 7.6
0.752
Case 30 12.0 5.0 -10.0 70.0 19.1
LE
Control 30 8.3 5.0 0.0 25.0 6.9
0.467
Case 30 12.0 5.0 -10.0 70.0 20.1
Mean Control 30 8.7 7.5 0.0 25.0 6.8
0.504
RE/LE Case 30 12.0 6.3 -10.0 70.0 19.1
9KHZ
RE
Control 30 10.0 10.0 0.0 30.0 8.2
0.006
Case 30 20.3 15.0 0.0 70.0 16.3
LE
Control 30 10.2 10.0 0.0 30.0 8.1
0.130
Case 30 18.8 10.0 0.0 80.0 21.9
Mean Control 30 10.1 10.0 0.0 30.0 7.7
0.019
RE/LE Case 30 19.6 13.8 0.0 75.0 18.6
10K
RE
Control 30 15.0 10.0 0.0 45.0 12.5
0.026
Case 30 25.5 20.0 0.0 90.0 20.8
LE
Control 30 13.2 10.0 0.0 50.0 11.3
0.011
Case 30 26.8 20.0 0.0 90.0 24.3
Mean Control 30 14.1 10.0 0.0 45.0 11.4
0.013
RE/LE Case 30 26.2 18.8 2.5 90.0 22.0
11.2K
RE
Control 30 12.7 7.5 0.0 50.0 12.0
0.005
Case 30 24.3 20.0 0.0 90.0 20.5
LE
Control 30 12.0 10.0 0.0 40.0 10.3
0.001
Case 30 26.8 20.0 0.0 85.0 23.0
Mean Control 30 12.3 7.5 0.0 42.5 10.8
0.001
RE/LE Case 30 25.6 18.8 2.5 87.5 21.0
12.5K
RE
Control 30 18.5 15.0 0.0 70.0 16.4
0.013
Case 30 30.0 20.0 0.0 80.0 20.7
LE
Control 30 19.0 17.5 0.0 65.0 15.7
0.007
Case 30 33.3 25.0 7.5 80.0 23.0
Mean Control 30 18.8 17.5 0.0 67.5 15.4
0.008
RE/LE Case 30 31.6 21.3 10.0 80.0 21.0
14K
RE
Control 29 16.2 15.0 0.0 55.0 11.0
0.001
Case 30 32.7 27.5 0.0 65.0 20.0
LE
Control 29 15.2 15.0 0.0 60.0 15.6
< 0.001
Case 30 33.2 30.0 5.0 65.0 21.2
Mean Control 29 15.7 15.0 0.0 57.5 12.7
< 0.001
RE/LE Case 30 32.9 26.3 7.5 65.0 19.8
16K
RE
Control 28 15.0 10.0 0.0 60.0 14.8
< 0.001
Case 30 38.0 40.0 10.0 60.0 19.3
LE
Control 28 17.0 10.0 0.0 55.0 17.3
< 0.001
Case 30 35.8 37.5 0.0 65.0 19.5
Mean Control 28 16.0 10.0 0.0 57.5 15.6
< 0.001
RE/LE Case 30 36.9 41.3 10.0 62.5 18.3
Continued Table 1.
The tested null hypothesis stated that the hyp-
acusis probabilities were the same for case and con-
trol group members, versus the alternate hypothesis 
in which probabilities are different.
Table 2 presents the results on the number of 
cases (percentages) according to group and p-values.
The case group had a statistically higher prob-
ability of hypacusis at any frequency, regardless of 
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hearing loss. This finding is similar to our study, as 
statistically significant (p = 0.008) higher probabilities 
of hypacusis were seen in the case group, with 23 
patients with hearing loss against the 12 in the same 
condition found in the control group.
Salvenelli et al.30 found higher levels of hearing 
deterioration in DM patients than in controls, with 
significant differences identified for all age ranges. 
Our study found similar results, but our groups were 
not statistically treated for age as a parameter.
Alvarenga et al.1 observed 33 individuals and, 
differently from this study, failed to find statistically 
significant differences between case and control 
groups.
Maia & Campos2 concluded that there is not 
enough evidence to establish DM as a cause of hea-
ring loss. They also stated that many papers appear 
to establish a direct connection between hearing 
loss and diabetes, while many others refute such 
association2.
Maia & Campos2 also offered a list of five pa-
pers published in the literature in which no direct 
link has been established between DM and hearing 
loss: Profazio & Barraveli (1959), Strauss et al.; (1982), 
Miller et al.; (1983), Axellson & Fagerberg (1968), and 
España et al.; (1995). Following is a list of 11 papers 
in which an association has been found between DM 
and hearing loss: Camisasca et al.; (1950), Jorgensen 
& Buch (1961), Tota & Bocci (1965), Marulo et al; 
(1974), Friedman et al; (1975), Taylor & Irwin (1978), 
Ferrer et al.; (1991), Cullen & Cinamond (1993), Tay 
et al.; (1995), Dalton et al.; (1998), and Karkalapudi 
et al.; (2003). This study is in agreement with the 
papers in which the association between DM and 
hearing loss was described2.
CONCLUSION
Audiological examination indicated the presence 
of statistically significant differences between case and 
control groups at 250, 500, 10000, 11200, 12500, 14000 
and 16000 Hz or both ears and mean values for both 
ears; and only right ears and mean values for both ears 
at 9.000 Hz.
Case group subjects were statistically more 
likely to have hypacusis in either ear and at all fre-
quencies.
Statistically significant differences were found 
between case and control groups through audio-
tested ears or frequencies, with 23 individuals versus 
12 controls.
DISCUSSION
Tay et al.47 reported higher incidence of hearing 
loss in DM patients at lower and middle frequencies 
(p < 0.001), as did another study from 1981 in which 
significant differences were found only at 2KHz48. A 
study done with 5,140 individuals in 2008,49 found 
diabetic subjects had reduced hearing in all frequen-
cies, and higher degrees of hypacusis at higher fre-
quencies. Within this range 54% of the subjects with 
diabetes had hearing loss. Twenty-one percent of 
the subejct with diabetes had hearing loss at low to 
mid-range frequencies.
In our study, the case group had a higher 
probability of having hearing loss. Statistically 
significant differences between case and control 
groups were seen at 250, 500, 10000, 11200, 12500, 
14000 and 16000 Hz or both ears and mean values 
for both ears; and only right ears and mean values 
for both ears at 9.000 Hz.
Patients had sensorineural hearing loss, 
predominantly at higher frequencies. Thirty-three 
(37.5%) of the tested 88 ears had hearing loss; 24 
(72.7%) ears had mild hearing loss and nine (27.3%) 
had moderate hearing loss. Twelve (27.3%) subjects 
had bilateral hearing loss5.
Mitochondrial deafness is a bilateral symmetri-
cal sensorineural type of hearing loss. The degree of 
impairment and age of onset vary, and it may or not 
be associated with syndromic conditions as DM27. 
This study showed higher probabilities of hearing 
loss in the case group (23 patients with hypacusis) 
when compared to the control group (12 patients).
Auditory acuity may be compromised in pa-
tients with dysfunctional glucose metabolism and 
insulin disorders regardless of their age. Marchiori 
& Gibrin3 reported data on a case group in which 
only one of 36 patients did not have hearing loss, 
and a control group in which 11 of 36 individuals had 
Table 2. Hypacusis probability at any frequency and either ear.
Hypacusis N
Control 
Group
Case 
Group
p-value
Yes 35 12 (40%) 23(76.7%)
0.008*
No 25 18 (60%) 7(23.3%)
N – number of subjects
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logical examination. Diabetes mellitus type 1 patients 
must be thoroughly examined from the audiological 
standpoint, as they are at risk of developing hearing 
loss. It is recommended that high frequency audi-
ometry be included in the patients’ clinical examination 
protocol.
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